open access

Vol 24, No 3 (2018)
Artykuły
Published online: 2018-10-25
Get Citation

Current evidence of rivaroxaban in cancer-associated thrombosis

Grzegorz Wojciech Halena, Agnieszka Kulik
DOI: 10.5603/AA.2018.0018
·
Acta Angiologica 2018;24(3):98-103.

open access

Vol 24, No 3 (2018)
Artykuły
Published online: 2018-10-25

Abstract

Patients with cancer have a high risk of developing cancer-associated thrombosis (CAT). Current guidelines suggest
preferential use of low molecular weight heparins (LMWH) in CAT. The real-world data show that compliance with
recommended LMWH therapy in cancer patients is low. Many patients discontinue injectable anticoagulants
prematurely, in some cases even after a month, despite a high recurrence rate in this population. In recent
years an increasing number of cancer patients are treated with direct oral anticoagulants, mainly rivaroxaban.
Recent data confirming the safety and efficacy of rivaroxaban are starting to emerge and support the growing
trend of using direct oral anticoagulants in cancer patients. If positive results of the recently completed SELECT-D
trial are confirmed in the upcoming trials and registries of CALLISTO project, the guidelines for the treatment
of CAT will have to be revised in favour of DOAC use in cancer-associated thrombosis.

Abstract

Patients with cancer have a high risk of developing cancer-associated thrombosis (CAT). Current guidelines suggest
preferential use of low molecular weight heparins (LMWH) in CAT. The real-world data show that compliance with
recommended LMWH therapy in cancer patients is low. Many patients discontinue injectable anticoagulants
prematurely, in some cases even after a month, despite a high recurrence rate in this population. In recent
years an increasing number of cancer patients are treated with direct oral anticoagulants, mainly rivaroxaban.
Recent data confirming the safety and efficacy of rivaroxaban are starting to emerge and support the growing
trend of using direct oral anticoagulants in cancer patients. If positive results of the recently completed SELECT-D
trial are confirmed in the upcoming trials and registries of CALLISTO project, the guidelines for the treatment
of CAT will have to be revised in favour of DOAC use in cancer-associated thrombosis.

Get Citation

Keywords

venous thromboembolism, cancer, cancer-associated thrombosis, direct oral anticoagulants, low molecular weight heparins, vitamin K antagonists

About this article
Title

Current evidence of rivaroxaban in cancer-associated thrombosis

Journal

Acta Angiologica

Issue

Vol 24, No 3 (2018)

Pages

98-103

Published online

2018-10-25

DOI

10.5603/AA.2018.0018

Bibliographic record

Acta Angiologica 2018;24(3):98-103.

Keywords

venous thromboembolism
cancer
cancer-associated thrombosis
direct oral anticoagulants
low molecular weight heparins
vitamin K antagonists

Authors

Grzegorz Wojciech Halena
Agnieszka Kulik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl